NAV

Rigosertib

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Rigosertib
DrugBank Accession Number
DB12146
Background

Rigosertib has been used in trials studying the treatment and basic science of MDS, RAEB, Cancer, Hepatoma, and Neoplasms, among others.

Type
Small Molecule
Groups
Investigational
Structure
3D
Similar Structures
Weight
Average: 451.49
Monoisotopic: 451.130087943
Chemical Formula
C21H25NO8S
Synonyms
  • Rigosertib
External IDs
  • ON 01910
  • ON-01910

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AmbroxolThe risk or severity of methemoglobinemia can be increased when Rigosertib is combined with Ambroxol.
ArticaineThe risk or severity of methemoglobinemia can be increased when Rigosertib is combined with Articaine.
BenzocaineThe risk or severity of methemoglobinemia can be increased when Rigosertib is combined with Benzocaine.
Benzyl alcoholThe risk or severity of methemoglobinemia can be increased when Rigosertib is combined with Benzyl alcohol.
BupivacaineThe risk or severity of methemoglobinemia can be increased when Rigosertib is combined with Bupivacaine.
ButacaineThe risk or severity of methemoglobinemia can be increased when Rigosertib is combined with Butacaine.
ButambenThe risk or severity of methemoglobinemia can be increased when Rigosertib is combined with Butamben.
CapsaicinThe risk or severity of methemoglobinemia can be increased when Rigosertib is combined with Capsaicin.
ChloroprocaineThe risk or severity of methemoglobinemia can be increased when Rigosertib is combined with Chloroprocaine.
CinchocaineThe risk or severity of methemoglobinemia can be increased when Rigosertib is combined with Cinchocaine.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Rigosertib Sodium406FL5G00V592542-60-4VLQLUZFVFXYXQE-USRGLUTNSA-M

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as alpha amino acids. These are amino acids in which the amino group is attached to the carbon atom immediately adjacent to the carboxylate group (alpha carbon).
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Alpha amino acids
Alternative Parents
Aminophenyl ethers / Methoxyanilines / Anisoles / Styrenes / Methoxybenzenes / Phenoxy compounds / Phenylalkylamines / Alkyl aryl ethers / Secondary alkylarylamines / Sulfones
show 7 more
Substituents
Alkyl aryl ether / Alpha-amino acid / Amine / Amino acid / Aminophenyl ether / Aniline or substituted anilines / Anisole / Aromatic homomonocyclic compound / Benzenoid / Carbonyl group
show 22 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
67DOW7F9GL
CAS number
592542-59-1
InChI Key
OWBFCJROIKNMGD-BQYQJAHWSA-N
InChI
InChI=1S/C21H25NO8S/c1-27-15-10-19(29-3)16(20(11-15)30-4)7-8-31(25,26)13-14-5-6-18(28-2)17(9-14)22-12-21(23)24/h5-11,22H,12-13H2,1-4H3,(H,23,24)/b8-7+
IUPAC Name
2-[(2-methoxy-5-{[(E)-2-(2,4,6-trimethoxyphenyl)ethenesulfonyl]methyl}phenyl)amino]acetic acid
SMILES
COC1=CC(OC)=C(\C=C\S(=O)(=O)CC2=CC=C(OC)C(NCC(O)=O)=C2)C(OC)=C1

References

General References
Not Available
PubChem Compound
6918736
PubChem Substance
347828442
ChemSpider
5293927
BindingDB
50060917
ChEBI
145417
ChEMBL
CHEMBL1241855
ZINC
ZINC000003942646
PDBe Ligand
6FS
Wikipedia
Rigosertib
PDB Entries
5j18 / 5j2r / 5ov7

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentChronic Myelomonocytic Leukemia / Cytopenias / Myelodysplastic Syndrome / Refractory Anemia With Excess of Blasts (RAEB)1
3CompletedTreatmentChronic Myelomonocytic Leukemia / Myelodysplastic Syndrome / Refractory Anemia With Excess of Blasts (RAEB)1
3CompletedTreatmentPancreatic Adenocarcinoma Metastatic1
3TerminatedTreatmentMyelodysplastic Syndrome / Refractory Anemia With Excess of Blasts (RAEB)1
2CompletedTreatmentAcute Myeloid Leukemia / Leukemias / Myelodysplastic Syndrome1
2CompletedTreatmentAnal Squamous Cell Carcinoma / Cervical Squamous Cell Carcinoma / Cutaneous Squamous Cell Carcinoma / Esophageal Squamous Cell Carcinoma (ESCC) / Penile squamous cell carcinoma / Squamous Cell Carcinoma of the Head and Neck (SCCHN) / Squamous Cell Carcinoma of the Lung1
2CompletedTreatmentMyelodysplastic Syndrome2
2CompletedTreatmentMyelodysplastic Syndrome / Trisomy 81
2CompletedTreatmentOvarian Cancer1
2TerminatedTreatmentAnemia / Leukemias / Myelofibrosis / Splenomegaly1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0226 mg/mLALOGPS
logP2.64ALOGPS
logP-0.25Chemaxon
logS-4.3ALOGPS
pKa (Strongest Acidic)2.27Chemaxon
pKa (Strongest Basic)5.24Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count9Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area120.39 Å2Chemaxon
Rotatable Bond Count11Chemaxon
Refractivity116.5 m3·mol-1Chemaxon
Polarizability46.32 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created at October 20, 2016 21:28 / Updated at February 21, 2021 18:53